2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
Wearable digital health technologies for monitoring in cardiovascular medicine
Wearable Digital Health Technologies for Monitoring in Cardiovascular Medicine | New England
Journal of Medicine Skip to main content The New England Journal of Medicine homepage …
Journal of Medicine Skip to main content The New England Journal of Medicine homepage …
2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with …
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart
Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection …
Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection …
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative …
Background Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin
receptor–neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] …
receptor–neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] …
CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction
M McDonald, S Virani, M Chan, A Ducharme… - Canadian Journal of …, 2021 - Elsevier
In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we
provide comprehensive recommendations and practical tips for the pharmacologic …
provide comprehensive recommendations and practical tips for the pharmacologic …
Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced
Background: In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic
Heart Failure With Reduced Ejection Fraction), empagliflozin reduced cardiovascular death …
Heart Failure With Reduced Ejection Fraction), empagliflozin reduced cardiovascular death …
Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease
Chronic kidney disease (CKD) as identified by a reduced estimated glomerular filtration rate
(eGFR) is a common comorbidity in patients with heart failure with reduced ejection fraction …
(eGFR) is a common comorbidity in patients with heart failure with reduced ejection fraction …
Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the Get …
JB Pierce, M Vaduganathan, GC Fonarow… - JAMA …, 2023 - jamanetwork.com
Importance Clinical guidelines for patients with heart failure with reduced ejection fraction
(HFrEF) strongly recommend treatment with a sodium-glucose cotransporter-2 inhibitor …
(HFrEF) strongly recommend treatment with a sodium-glucose cotransporter-2 inhibitor …
Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure—optimizing therapy with the need for speed
Many eligible patients with heart failure (HF) with reduced ejection fraction (HFrEF) never
receive therapies shown to extend survival or receive them with much delay. 1, 2 Multiple …
receive therapies shown to extend survival or receive them with much delay. 1, 2 Multiple …
Understanding the complexity of heart failure risk and treatment in black patients
A Nayak, AJ Hicks, AA Morris - Circulation: Heart Failure, 2020 - Am Heart Assoc
Although care of patients with heart failure (HF) has improved in the past decade, important
disparities in HF outcomes persist based on race/ethnicity. Age-adjusted HF-related …
disparities in HF outcomes persist based on race/ethnicity. Age-adjusted HF-related …